Earnings
CRISPR Therapeutics' $12.7 Million Quarter Rests On A Vertex Option That Vertex Passed On
Previously deferred Vertex money drove third-quarter revenue to $12.7 million, while the quarterly net loss widened to $111.4 million.
CRSP
CRISPR Therapeutics (CRSP) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Casgevy Sales Hit $99 Million, Nearly Six Times Last Year, As CRISPR's Loss Widens To $111.4 Million
CRISPR Therapeutics holds $2,276.6 million in cash and won two FDA fast-track-style designations for its cholesterol-editing drug.
SEC Filings
CRISPR Therapeutics Names Finance Insider Andrew Silver CFO As Raju Prasad Resigns
An 8-K says Prasad's exit is not tied to any disagreement over accounting, and Silver's pay is set at $515,000 a year.